Esophageal Squamous Cell Carcinoma clinical trials

Explore recruiting esophageal squamous cell carcinoma clinical trials.

Recruiting esophageal squamous cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Esophageal Squamous Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SAFE-ESO_Phase II study evaluating safety and efficacy of Tislelizumab for elderly patients unfit for chemotherapy, with advanced esophageal squamous-cell carcinoma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The NEEDS Trial)

Ireland, Sweden, Norway, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK‑3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B

Norway, Germany, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

TGF-β And PDL-1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Czechia, Germany, France, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Untreated Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Czechia, Germany, Italy, France, Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Esophageal Squamous Cell Carcinoma trials by city

Esophageal Squamous Cell Carcinoma in Toronto Esophageal Squamous Cell Carcinoma in Vancouver Esophageal Squamous Cell Carcinoma in Montreal Esophageal Squamous Cell Carcinoma in Calgary Esophageal Squamous Cell Carcinoma in Edmonton Esophageal Squamous Cell Carcinoma in Ottawa Esophageal Squamous Cell Carcinoma in Winnipeg Esophageal Squamous Cell Carcinoma in Quebec City Esophageal Squamous Cell Carcinoma in Hamilton Esophageal Squamous Cell Carcinoma in Kitchener Esophageal Squamous Cell Carcinoma in London Esophageal Squamous Cell Carcinoma in Halifax Esophageal Squamous Cell Carcinoma in New York Esophageal Squamous Cell Carcinoma in Los Angeles Esophageal Squamous Cell Carcinoma in Chicago Esophageal Squamous Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease